一品红(300723) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥622,870,629.55, a decrease of 13.01% compared to the same period last year[7]. - Net profit attributable to shareholders was ¥100,512,059.02, down 9.53% year-on-year[7]. - The net profit after deducting non-recurring gains and losses increased by 5.16% to ¥98,009,396.71[7]. - Total revenue for the reporting period was CNY 622,870,629.55, a decrease of 13.0% from CNY 716,001,917.53 in the previous period[42]. - The company's net profit attributable to shareholders was CNY 1,462,311,122.82, up from CNY 1,361,799,063.80, reflecting an increase of 7.4%[42]. - Basic earnings per share decreased to 0.2213 from 0.2446, a decline of 9.0%[45]. - The net profit for the current period is CNY 95,487,011.59, a decrease of 8.5% compared to CNY 104,375,558.02 in the previous period[65]. - Operating profit for the current period is CNY 114,188,011.79, down from CNY 125,512,970.22, reflecting a decline of 9.6%[65]. - The total profit for the current period is CNY 111,695,404.30, down 12.0% from CNY 126,843,020.37 in the previous period[65]. - The company reported a decrease in income tax expenses to CNY 16,208,392.71 from CNY 22,467,462.35, a reduction of 28.0%[65]. Cash Flow and Investments - Operating cash flow increased significantly by 67.35% to ¥54,218,604.87[7]. - The net cash flow from operating activities increased by 67.35% to ¥54,218,604.87 compared to ¥32,399,255.97 in the same period last year[32]. - Cash received from other operating activities decreased by 78.74% to ¥8,614,721.86 from ¥40,525,892.06 year-on-year[32]. - Cash paid for purchasing goods and services rose by 44.24% to ¥231,081,772.51, primarily due to increased raw material purchases[32]. - Investment cash payments increased by 83.21% to ¥545,943,820.43, reflecting a rise in low-risk short-term financial investments[32]. - Cash received from borrowings increased by 50.00% to ¥750,000,000.00, aimed at funding raw material production base construction and daily operations[32]. - Cash paid for debt repayment surged by 280.00% to ¥380,000,000.00, primarily due to the maturity of previously raised bank loans[32]. - The net cash flow from investment activities was -454,629,300.21, compared to -269,438,376.20 in the previous year, indicating a significant increase in cash outflow[48]. - The cash inflow from investment activities totaled CNY 188,217,619.36, compared to CNY 215,185,172.96 in the previous period, reflecting a decrease of 12.5%[67]. - The company paid CNY 200,700,921.70 in other cash related to operating activities, down from CNY 356,698,591.57, a decrease of 43.7%[67]. Research and Development - The company invested ¥62,529,200 in R&D, a year-on-year increase of 29.94%[28]. - The company has established a collaborative research and development mechanism to enhance its innovative drug development capabilities[38]. - The company has 133 ongoing projects, including 7 innovative drug projects, enhancing its product pipeline[29]. - The AR882 capsule for treating primary gout with hyperuricemia has entered phase II/III clinical trials, aiming to enroll approximately 636 patients[28]. - The company initiated a multi-center, randomized, double-blind, parallel-controlled Phase II/III clinical trial for the innovative drug AR882, targeting approximately 636 patients, with completion expected by year-end if progress is smooth[36]. - Research and development expenses increased to CNY 62,529,225.11, up from CNY 48,121,692.21, marking a rise of 30.0%[42]. - Research and development expenses rose by 29.94% to 62,529,225.11, reflecting increased spending on R&D projects[50]. - The company obtained a registration certificate for a new product, benazepril hydrochloride suspension, indicating ongoing product development efforts[56]. Assets and Liabilities - Total assets increased by 5.61% to ¥4,652,399,083.32 compared to the end of the previous year[7]. - The total assets of the company amounted to CNY 4,652,399,083.32, compared to CNY 4,405,295,590.95 at the beginning of the period, indicating a growth of 5.6%[42]. - The total liabilities rose to 1,958,990,336.68 from 1,807,373,855.90, indicating an increase in the company's financial obligations[61]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,159, with Guangdong Guangrun Group holding 40.43% of shares[32]. - Major shareholders include Wu Meirong with 5.61% and Li Hanxiong with 5.47%[33]. - The company has a total of 183,600,000 shares held by Guangdong Guangrun Group, which is the largest shareholder[33]. - There are no shareholders participating in margin trading activities[34]. Miscellaneous - The weighted average return on equity decreased to 3.93% from 5.27% year-on-year[7]. - The company expects to enter a new stage of high-quality development as economic vitality continues to improve[11]. - The company reported a significant reduction in sales expenses, which fell to CNY 216,105,845.55 from CNY 389,791,453.93, a decrease of 44.4%[42]. - Operating costs increased by 49.75% to 150,913,113.73 due to the completion of a new production facility and higher manufacturing costs[50]. - The company has not undergone an audit for the first quarter report[69].